

1-1-2020

Minimizing Blood Loss in Spine Surgery.

Christopher Mikhail

Zach Pennington

Paul M Arnold

Darrel S Brodke

Jens R Chapman

See next page for additional authors

Follow this and additional works at: <https://jdc.jefferson.edu/neurosurgeryfp>



Part of the [Neurology Commons](#), and the [Surgery Commons](#)






[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Christopher Mikhail, Zach Pennington, Paul M Arnold, Darrel S Brodke, Jens R Chapman, Norman Chutkan, Michael D Daubs, John G DeVine, Michael G Fehlings, Daniel E Gelb, George M Ghobrial, James S Harrop, Christian Hoelscher, Fan Jiang, John J Knightly, Brian K Kwon, Thomas E Mroz, Ahmad Nassr, K Daniel Riew, Lali H Sekhon, Justin S Smith, Vincent C Traynelis, Jeffrey C Wang, Michael H Weber, Jefferson R Wilson, Christopher D Witiw, Daniel M Sciubba, and Samuel K Cho

Minimizing Blood Loss in Spine Surgery

Christopher Mikhail, MD¹, Zach Pennington, BS¹ , Paul M. Arnold, MD¹ , Darrel S. Brodke, MD¹, Jens R. Chapman, MD¹, Norman Chutkan, MD, FACS¹, Michael D. Daubs, MD¹, John G. DeVine, MD¹ , Michael G. Fehlings, MD, PhD, FRCSC, FACS¹ , Daniel E. Gelb, MD¹, George M. Ghobrial, MD¹ , James S. Harrop, MD¹, Christian Hoelscher, MD¹, Fan Jiang, MDCM, PhD¹ , John J. Knightly, MD¹, Brian K. Kwon, MD, PhD, FRCSC¹, Thomas E. Mroz, MD¹, Ahmad Nassr, MD¹, K. Daniel Riew, MD¹, Lali H. Sekhon, MD¹, Justin S. Smith, MD¹, Vincent C. Traynelis, MD¹, Jeffrey C. Wang, MD¹, Michael H. Weber, MD, MSc, PhD, FRCSC¹, Jefferson R. Wilson, MD, PhD, FRCSC¹ , Christopher D. Witiw, MD, MS¹, Daniel M. Sciubba, MD¹ , and Samuel K. Cho, MD¹ 

Global Spine Journal
2020, Vol. 10(1S) 71S-83S
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2192568219868475
journals.sagepub.com/home/gsj



Abstract

Study Design: Broad narrative review.

Objective: To review and summarize the current literature on guidelines, outcomes, techniques and indications surrounding multiple modalities of minimizing blood loss in spine surgery.

Methods: A thorough review of peer-reviewed literature was performed on the guidelines, outcomes, techniques, and indications for multiple modalities of minimizing blood loss in spine surgery.

Results: There is a large body of literature that provides a consensus on guidelines regarding the appropriate timing of discontinuation of anticoagulation, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and herbal supplements prior to surgery. Additionally, there is a more heterogeneous discussion the utility of preoperative autologous blood donation facilitated by erythropoietin and iron supplementation for healthy patients slated for procedures with high anticipated blood loss and for whom allogeneic transfusion is likely. Intraoperative maneuvers available to minimize blood loss include positioning and maintaining normothermia. Tranexamic acid (TXA), bipolar sealer electrocautery, and topical hemostatic agents, and hypotensive anesthesia (mean arterial pressure (MAP) <65 mm Hg) should be strongly considered in cases with larger exposures and higher anticipated blood loss. There is strong level I evidence for the use of TXA in spine surgery as it reduces the overall blood loss and transfusion requirements.

Conclusion: As the volume and complexity of spinal procedures rise, intraoperative blood loss management has become a pivotal topic of research within the field. There are many tools for minimizing blood loss in patients undergoing spine surgery. The current literature supports combining techniques to use a cost-effective multimodal approach to minimize blood loss in the perioperative period.

Keywords

intraoperative, blood, loss, transfusions, NSAIDs, aspirin, topical, hemostatic, agents, donation

Introduction

Over the past few decades, the number of spinal procedures performed in the United States has increased dramatically, with growth exceeding 200% since the 1990s.¹⁻⁴ As the volume and complexity of spinal procedures rise, intraoperative blood loss management has become a pivotal topic of research within the

¹ Icahn School of Medicine at Mount Sinai, New York, NY, USA

Corresponding Author:

Samuel K. Cho, Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY 10029, USA.
Email: samuel.cho@mountsinai.org



Creative Commons Non Commercial No Derivatives CC BY-NC-ND: This article is distributed under the terms of the Creative Commons Attribution-Non Commercial-NoDerivatives 4.0 License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

field.⁵⁻⁷ Many spinal procedures are associated with substantial blood loss. Notable are revision surgeries to treat deformity, which also have the highest incidence of postoperative transfusion, ranging from 8% to 30%.⁸⁻¹⁰ Certain patient characteristics, namely advanced age, higher body mass index (BMI), greater surgical complexity, and longer fusion constructs are all associated with more extensive blood loss.⁶

Transfusions—the traditional answer to clinically relevant blood loss—are themselves associated with a myriad of complications, including the transmission of bloodborne infection, immunologic cross-reactions, thromboembolic events, and immunosuppression.¹¹⁻¹³ These complications can lead to longer hospital stays, increased direct costs, and higher inpatient mortality.^{5,14,15} To this end, postoperative transfusion has been demonstrated by several recent, large retrospective reviews in spine and nonspine population to increase perioperative mortality, complication rate, and overall care costs.^{11,16-20} Among the most concerning complications include significant fluid shifts capable of damaging the heart, lung, and kidneys, such as circulatory overload, transfusion-related acute lung injury, and acute kidney injury.

Owing to this significant side-effect profile, it is incumbent upon the practicing spine surgeon to possess in their armamentarium those interventions capable of reducing intraoperative blood loss and transfusion needs. Here, we provide a narrative review of the recent evidence, highlighting both the preoperative and intraoperative techniques demonstrated to best reduce perioperative blood loss in spine surgery.

Preoperative Prevention

More than 90% of aged Americans currently use one or more prescription medications, over-the-counter medications, or dietary supplements.²¹ Many of these either directly or indirectly affect the intraoperative bleeding risk through inhibition of the coagulation pathways or platelet function. Therefore, a thorough, timely review of medications prior to elective spine surgery is recommended to decrease otherwise avoidable blood loss.

Nonsteroidal Anti-Inflammatory Drugs

The most common medications of concern are the nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin (acetyl salicylic acid [ASA]), ibuprofen, naproxen, and celecoxib. These medications inhibit the cyclo-oxygenase (COX) enzymes, decreasing the production of thromboxane A₂ (TXA₂), a key upstream trigger of platelet activation and aggregation. Despite conventional wisdom recommending their perioperative discontinuation, there remain no actual guidelines as to the optimal timing for cessation. Most recommendations are based on the pharmaceutical half-lives of these drugs, yet there is a lack of high-quality evidence in the field of spine surgery to suggest the optimal timing of discontinuation.²² Consequently, it is observed that most surgeons agree to an arbitrarily defined number of days prior to surgery.²³ In a recent survey of the Canadian Spine Society, the majority

agreed that discontinuation of antiplatelet agents 7 days prior to surgery was one of the most important measures for limiting intraoperative blood loss, with nearly all members endorsing routine use of this practice.⁷

Here, it is worth emphasizing the influence of aspirin on intraoperative bleeding. With the increased prevalence of coronary vascular disease and the documented ability of regular aspirin usage to lower the risk for coronary events, aspirin holds a unique place within the NSAID family. While it is generally held that aspirin should be discontinued on the same time frame as other antiplatelet agents, the preponderance of evidence has failed to demonstrate an appreciable effect on either blood loss or overall complication rate among patients undergoing spinal surgery.²⁴⁻²⁶ Therefore, we provide only a weak recommendation for its discontinuation in patients with no reasonable indication for continued use. This may help decrease postoperative bleeding from the wound site.²⁷

Antiplatelet Agents

Many NSAIDs, aspirin in particular, also function as antiplatelet agents owing to their ability to impair thromboxane A₂ production, of chief concern here are P2Y₁₂ antagonists (eg, clopidogrel, prasugrel, ticagrelor, and ticlopidine). These agents have elimination half-lives of 6 to 15 hours²⁸ and their discontinuation is recommended by the vast majority of spine surgeons.²³ However, prior evidence has failed to correlate a significant intraoperative bleeding risk with preoperative antiplatelet agent review. One meta-analysis of 46 studies found that continuing either aspirin or a P2Y₁₂ antagonist (clopidogrel) during the perioperative period was not associated with a significant increase in intraoperative blood loss or transfusion risk.²⁹ Level II evidence from a nonblinded clinical trial also failed to demonstrate a difference in blood loss, transfusion rate, or complication rate between patients taking clopidogrel and controls.³⁰ Because of this, as well as the presence of inconsistency among guidelines on the necessity of perioperative discontinuation of antiplatelet therapy, we believe it is safe to continue patients on antiplatelet therapy prior to spine surgery. However, for those desiring to minimize the risk of massive intraoperative blood loss, the recommended discontinuation time frames can be found in Table 1.

Anticoagulants

Unlike NSAIDs, a clear consensus exists on the decision to discontinue therapeutic anticoagulants preoperatively. Warfarin should be stopped 5 days prior to surgery with a target international normalized ratio (INR) of 1.4 or less; heparin bridging therapy can then be implemented to prevent venous thrombotic events (VTEs) in high-risk patients. Newer anticoagulants—direct thrombin inhibitors (eg, dabigatran, argatroban) and Xa inhibitors (eg, apixaban, rivaroxaban)—may be continued until 3 days prior to surgery due to their shorter half-lives. Heparin bridging is not as well described after the halting of these medications, but it may be indicated for patients at

Table 1. Drugs that May Increase Surgical Blood Loss.

Drugs That Should Be Stopped Prior to Surgery			
Drug Class	Mechanism of Action	Drug Names	Minimum Cessation Time ^a
NSAIDs	Nonselective COX inhibition	Diclofenac, Ibuprofen, Celecoxib*	1 day
		*Selective COX 2	Indomethacin, Ketorolac, Etodolac, Sulindac, Naproxen
	*Reversible	Piroxicam	7 days
		Aspirin ^b	7 days
Platelet Inhibitors	Irreversible ADP receptor inhibition	Clopidogrel, Prasugrel	7 days
		Ticagrelor*	5 days
	*Reversible	Ticlopidine	14 days
Anticoagulants	Irreversibly inhibit thrombin	Low-molecular-weight heparin	1 day
		Unfractionated heparin	4-5 hours
	Reversibly inhibit thrombin	Dabigatran, Rivaroxaban, Apixaban, Endoxaban	3 days
		Vitamin K inhibitor	Warfarin

Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclo-oxygenase; ADP, adenosine diphosphate.

^a Minimum cessation time is based on reducing the risk of intraoperative bleeding.

^b Aspirin is also an irreversible platelet inhibitor.

^c Must check international normalized ratio of 1.4 or less.

*The asterisk in each section refers to the asterisk in the next column.

high risk of thromboembolic events. Work-up with the CHADS₂, CHADS₂-VASc (clinical prediction rules for estimating the risk of stroke in patients with nonrheumatic atrial fibrillation), or HAS-BLED scoring system (developed to assess 1-year risk of major bleeding in patients taking anticoagulants with atrial fibrillation),³¹ and consultation with hematology may be considered for these patients (Table 2). Table 1 provides current guidelines where available on when to stop specific medications in order to minimize intraoperative blood loss caused by these medications.

It should be noted that numerous other prescription and non-prescription medications (eg, multivitamins) can significantly alter successful coagulation cascade function. Typically, any anti-inflammatory medication or nutritional supplement can induce more bleeding. Particularly important are herbal and dietary supplements, which are used by more than 60% of Americans³⁶ and commonly missed during medication reviews.²¹ Many herbal and dietary supplements have been associated with increased surgical and postoperative bleeding, including St John's wort, garlic, ginseng, saw palmetto, and fish oil.³⁷⁻³⁹ We suggest also discontinuing these supplements prior to planned spine surgery.

Preoperative Autologous Blood Transfusion and Erythropoietin

Another method proposed to reduce transfusion risks for elective cases with high anticipated blood loss is preoperative autologous blood donation (PABD). Though valuable in theory, the evidence supporting this method has been mixed with some studies reporting decreases in allogeneic transfusion rate by up to 50%,^{40,41} while others found an increased rate of transfusion and no difference in outcomes.⁴² The latter likely reflects the use of PABD in patients with inadequate compensatory erythropoiesis

between phlebotomy and surgery. To avoid this, we recommend 2 steps. In patients considering PABD, a hemoglobin (Hb) level should be obtained 3 to 4 weeks prior to surgery; those found to be anemic (Hb < 11 g/dL) should be dissuaded from PABD or optimized using erythropoietin and iron supplementation. Similarly, for those pursuing PABD that subsequently demonstrate signs of PABD-induced anemia, erythropoietin (40 000 units SQ q7d beginning 4 weeks before surgery) and iron supplements (FeSO₄—325 mg orally thrice a day for 4 weeks before surgery) can be administered preoperatively.⁴³ Erythropoietin (EPO) significantly improves preoperative Hb levels, decreases allogeneic transfusion requirements, and decreases hospital length of stay.⁴⁴ However, PABD with preoperative EPO treatment is insufficient to eliminate the risk of perioperative transfusion and up to 40% of patients may still require transfusion of one or more units of allogeneic blood products.⁴⁵ One should note that EPO use is considered off-label for patients willing to preoperatively donate autologous blood; Food and Drug Administration (FDA) approval is only for those with perioperative hemoglobin levels between 10 and 13 g/dL who are unwilling to donate blood preoperatively.⁴⁶ Consequently, PABD with concomitant EPO administration may be one strategy for reducing transfusion requirements. However, the overall recommendation for its use is based largely on retrospective series from the pediatric deformity literature and may not be applicable to adult patients. This is especially true for older patients with a lower baseline hematocrit in whom PABD may simply shorten the time to first transfusion. Additionally, evidence suggests that red cell viability and function decrease semilinearly with storage time,⁴⁷ so it may be that the extent of red cell degeneration seen during the preoperative period required for anemia resolution nullifies any potential benefit. For these reasons, as well as the risk of transfusion reaction secondary to clerical error, the use of PABD has fallen out of favor over the past 2 decades.

Table 2. Preoperative Scoring Systems for Relative Risk of Thromboembolic and Hemorrhagic Complications in Patients on Preoperative Anticoagulants (Sources³¹⁻³⁵).

Scale	CHADS ₂	CHADS ₂ VASc	HAS-BLED	HEMORR ₂ -HAGES	ATRIA–Stroke	ATRIA–Bleed
Used for	Stroke risk	Stroke risk	Major bleeding when on anticoagulation	Major bleeding in elderly patients with Afib	Stroke risk	Bleeding risk in patient on warfarin
Score	Element CHF HTN Age ≥75 y DM Prior CVA/TIA	Element CHF HTN Age ≥75 y DM Prior CVA/TIA PVD/MI Age 65-74 y Female sex	Element HTN ESRD Liver disease Prior CVA/TIA Prior major bleed Labile INR Age >65 y On antiplatelets or anticoagulants	Element Liver/kidney disease EtOH abuse Hx cancer Age >75 y ↓ Platelet count or function Prior major bleed HTN Anemia CYP 2C9 mutation ↑ Fall risk Prior CVA/TIA	Element Prior CVA/TIA Age Female sex DM CHF HTN Proteinuria ESRD	Element Anemia ESRD Age ≥75 y Prior major bleed HTN
Patients	1 1 2 1 2	1 1 2 1 2 1 1 1	1 1 1 1 1 1 1 1	1 1 1 1 1 2 1 1 1 1	1 1 1 1 1 1 1 1 1	3 3 1 1 1 1 1
Risk ^a	0.6% 3.0% 4.2% 7.1% 11.1% 12.5% 13.0%	0.2% 0.6% 2.2% 3.2% 4.8% 7.2% 9.7% 11.2% 10.8% 12.2%	—	—	—	—
Risk ^b	—	0 1 2 3 4 5-9	—	—	—	—
Risk ^c	—	1.13 1.02 1.88 3.74 8.70	—	—	—	—
Risk ^d	—	0.2% 0.6% 2.2% 3.2% 4.8% 7.2% 9.7% 11.2% 10.8% 12.2%	—	—	—	—
Score	0 1 2 3 4 5 6	0 1 2 3 4 5 6 7 8 9	—	0 1 2 3 4 ≥ 5	0 1 2 3 4 5 6 7 8 ≥ 9	0 1 2 3 4 5 6 7 8 9-10
Score ^e	0.40 0.55 0.97 1.01 2.62 5.65 4.95 5.17 9.61 12.4-17.3	—	—	—	—	—

Abbreviations: Afib, atrial fibrillation; CHF, congestive heart failure; CVA, cerebral vascular accident; DM, diabetes mellitus; ESRD, end-stage renal disease; HTN, hypertension; Hx, history of MI, myocardial infarction; PVD, peripheral vascular disease; TIA, transient ischemic attack.

^a Risk is annual stroke rate.

^b Bleeds per 100 patient-year.

^c Bleeds per 100 patient-year.

^d Thromboembolic events per 100 patient-year.

^e Bleeds per 100 patient-year.

Intraoperative Blood Loss Management

Positioning

Appropriate surgical positioning is an underappreciated means of decreasing intraoperative blood loss. Two considerations include (1) the relative positions of the surgical site and right atrium and (2) the intra-abdominal pressure (IAP). For operations on the lumbar and lower thoracic spine, placing the patient into a Trendelenburg position can reduce pressure in the inferior vena cava and consequently decrease bleeding from the epidural and vertebral venous plexuses; reverse Trendelenburg offers similar benefits in cervical procedures.

Appropriate table selection can also help facilitate hemostasis for requiring prone positioning. Conventional surgical tables elevate IAP, in turn causing congestion of the epidural venous plexus—a common source of bleeding.⁴⁸ To avoid this, a Jackson table or a Wilson frame with wide interpad spacing can be employed, as both allow free suspension of the abdomen, decreasing IAP and draining blood away from the operative site. Alternatively, for those centers without this option, adoption of the jackknife position can reduce IAP and blood loss relative to standard prone positioning for single level lumbar surgery.^{49,50}

Normothermia

Maintaining core temperature at physiological levels has also been proposed to reduce blood loss by preventing hypothermia-induced coagulopathy. The intervention has been only poorly explored in spine, and several groups have failed to document an impact of core temperature on blood loss.^{51,52} Paradoxically, a meta-analysis of studies from other surgical fields reported even mild hypothermia to reduce total blood loss and decrease transfusion rates.⁵³ Consequently, the ability of hypothermia to reduce blood loss is questionable. Perioperative hypothermia is associated with increased complication rates and mortality though,⁵⁴ recommending its use for all patients despite its questionable link to superior hemostatic outcomes. Strategies to prevent hypothermia include forced air warming,⁵⁵ warm socks,⁵⁶ warmed intravenous fluids, and warmed irrigation fluids.⁵⁷

Hypotensive Anesthesia

Control of the mean arterial pressure (MAP) is a constant dialogue between surgeon and anesthesiologist. An experienced anesthesiologist is often able to strike a balance between the perfusion demands of vital organs and the surgeon's request for a low MAP due to its ability to minimize intraoperative blood loss.

Verma et al⁵⁸ reported that maintaining a MAP of 65 mm Hg or less reduced blood loss in deformity cases by 33%. However, such low MAPs can place the spinal cord at risk of infarction, especially in cases whereby the spinal cord is previously injured or already under compression (eg, cervical spondylotic myelopathy). To prevent this rare, but catastrophic event, intraoperative neuromonitoring should be used as it allows for early detection of spinal cord hypoperfusion and can consequently prevent permanent neurological deficits in the

overwhelming majority of cases.⁵⁹⁻⁶¹ Hypotensive anesthesia (MAP \leq 70 mm Hg) may be best reserved for the approach and instrumentation, where bleeding risk is highest. However, we recommend maintaining the MAP above 80 mm Hg while manipulating the neural elements to decrease the likelihood of ischemic tissue injury. This recommendation is strongest for patients with increased risk of ischemic complications at baseline, such as those with peripheral vascular disease, a history of ischemic events (e.g., stroke), chronic renal failure, or uncontrolled diabetes mellitus.⁶² Overall, we caution against the use of hypotensive anesthesia when there is risk of neurologic injury from poor perfusion.

Surgical Approach

The conventional, midline approach is the most common approach employed for posterior spine surgeries. During dissection, care is taken to remain in the avascular plane formed by the fascial sheaths of the 2 paraspinal muscular bundles. This is then continued laterally in a subperiosteal dissection to the facets, past which dissection begets more bleeding. Use of a Wiltse or paraspinal, muscle-splitting approach has been suggested to decrease blood loss relative to the midline approach.⁶³ However, the evidence to support this is relegated to a single retrospective study. Consequently, we make no recommendations regarding surgical approach for the reduction of operative blood loss.

Electrocautery

Since its introduction by Harvey Cushing in the early 1900s, electrocautery has helped reduce blood loss in neurosurgical procedures. Conventional techniques have made use of both monopolar and bipolar cautery for the dissection of soft tissues and coagulation of bleeding vessels, respectively. In 2008, pre-market approval was granted for a bipolar sealer device, which employs radiofrequency energy with concomitant saline irrigation.⁶⁴ The use of saline helps significantly reduce surgical site temperatures relative to conventional electrocautery methods, and consequently may reduce trauma to the dissected tissues.

Multiple studies evaluating this device have demonstrated reductions in blood loss, operation duration, and transfusion requirements.⁶⁵⁻⁶⁸ At the same time, these same studies documented no difference in major complications, hospital length of stay, or infection rate between patients operated using the bipolar sealer and conventional electrocautery tools.^{65,66,69,70} Furthermore, a recent meta-analysis by Lan and colleagues⁶⁹ suggested that the use of a bipolar sealer can reduce operative times, intraoperative blood loss, and transfusion rates. Last, a randomized controlled trial published by Wang et al⁷¹ on a series of patients undergoing surgery for degenerative scoliosis of the lumbar spine also found the use of a bipolar sealer to reduce operation time, intraoperative blood loss, transfusion rates, and mean transfusion requirements. Therefore, the use of a bipolar sealer in larger exposure spine surgery may be

recommended, with the given that meticulous surgical techniques are employed to control bleeding throughout surgery.

Antifibrinolytics

One of the greatest advancements in minimizing blood loss during spine surgery has been the introduction of antifibrinolytic agents, which in select studies have been demonstrated to reduce blood loss by up to 50%.⁷² With the withdrawal of aprotinin from the US market in 2008, the 2 main antifibrinolytics in clinical practice are tranexamic acid (TXA) and ϵ -aminocaproic acid (EACA). Both compounds are lysine analogues that bind to and prevent activation of plasminogen, thereby inhibiting fibrinolysis and promoting clot stabilization. Despite concern that such a procoagulation mechanism of action may increase the risk of postoperative VTEs, this concern has failed to be borne out in the literature.^{73,74} The few FDA-defined contraindications to the use of these agents include active bleeding (e.g., epidural hematoma, subarachnoid hemorrhage), acquired defective color vision (TXA only), active intravascular clotting, and known hypersensitivity to the anti-fibrinolytic acid being used.

ϵ -Aminocaproic Acid

EACA has been found to be a safe and effective antifibrinolytic agent in spine surgery by multiple prospective randomized controlled trials (RCTs).⁷⁵⁻⁷⁸ Studies examining its use have typically employed a loading dose of 100 mg/kg with a maintenance dose of 10 mg/kg/h. EACA has been used with both anterior and posterior surgical approaches for multiple indications, including pediatric deformity and adult degenerative pathologies. In the most recent study examining EACA use in patients operated for adolescent idiopathic scoliosis, EACA did not lower intraoperative blood loss (EBL), but it was associated with significantly decreased total blood loss during the hospital stay with the treatment group averaging 2400 ml/case compared to 4100 mL/case in controls ($P < .0007$).⁷⁶ It is speculated that this benefit is derived from the continuous effect of the EACA infusion, as both intraoperative blood loss and postoperative drainage were only marginally lower, but the cumulative effect was statistically significant. Other RCTs all demonstrated significantly lower estimated blood loss with use of EACA without any significant difference in complications between groups.

Tranexamic Acid

TXA has many applications in minimizing blood loss outside surgery, including leukemia, ocular hemorrhage, trauma with active hemorrhage, severe hemoptysis, and menorrhagia. TXA was first introduced surgically in the setting of high-risk cardiac surgery where it successfully reduced blood transfusion requirements and cost. It was soon widely adopted in the field of orthopedic arthroplasty, where it demonstrated similar benefits. TXA is 7 to 10 times more potent than EACA,⁷⁹ allowing

for commensurately lower doses. On review of the current literature, the most commonly used regimen employs a loading dose of 10 mg/kg and maintenance dosing of 1 to 2 mg/kg/h. As with EACA, class I evidence exists supporting the ability of TXA to reduce intraoperative blood loss. A recent meta-analysis of pooled data of 6 randomized placebo-controlled trials demonstrated a mean decrease in intraoperative blood loss of 229 mL ($P < .00001$).⁷⁴ As with EACA, TXA may continue to provide hemostatic benefits postoperatively. A prospective randomized, controlled trial of patients undergoing cervical laminoplasty failed to demonstrate a significant decrease in intraoperative blood loss with TXA administration. However, the authors did find total blood loss to be significantly lower ($P < .01$).⁸⁰ As with the aforementioned studies assessing its use in thoracolumbar fusion, the authors observed no significant difference in the VTE rates.^{73,76,80-85} In the past year, Lin et al⁸⁶ published on the use of a high-dose TXA (50 mg/kg loading dose with a 5 mg/kg/h maintenance infusion), which they found to have complication rates comparable to historical cohorts using a conventional, low-dose regimen. Subsequent to this, a prospective, randomized controlled trial (NCT02053363) has been initiated comparing the two regimens, with results expected in mid-2019.⁸⁷

Both TXA and EACA are powerful agents in minimizing blood loss compared with placebo controls. Meta-analysis pooling results from 12 prospective randomized trials using either TXA or EACA for adults undergoing spinal fusion⁷⁴ found antifibrinolytic use to reduce intraoperative blood loss by a mean of 127 mL ($P < .002$) and postoperative blood loss by a mean of 95 mL ($P < .009$). The use of either antifibrinolytic also significantly lowered both the rate of allogeneic red blood cell (RBC) transfusion (odds ratio = 0.58, $P < .04$) and the mean units transfused. Ultimately, the use of these agents is supported by a high level of evidence (Table 3) and should be strongly considered in patients undergoing surgery with high anticipated blood loss. We express no strong preference between the two antifibrinolytics, although TXA has been demonstrated to provide superior hemostatic benefits in at least one recent study.⁸⁸ From a cost-effectiveness aspect, TXA may be preferable as it is readily available in generic form and has been found to be a cost-effective method of minimizing blood loss.⁸⁴

Of note, topical and oral formulations of tranexamic acid are now available. Prior meta-analyses in the joint arthroplasty literature have demonstrated topical, oral, and intravenous formulations to have similar effects on intraoperative blood loss as well as similar complication rates.^{89,90} Similar evidence is not yet available in the field of spine surgery though.⁹¹ Additionally, the use of topical TXA in addition to intravenous TXA may further decrease blood loss, hemoglobin decrease, and transfusion requirement.⁹² Insufficient evidence exists to compare complication profiles in patients with high preoperative risks of thromboembolic events; however, we speculate that the topical formulation may be more advantageous for this population owing to its more local effects.

Table 3. Antifibrinolytics Literature Review.

Publication	Study Design	Patients (Controls)	Mean Δ EBL (cm ³)	Complications Odds Ratio
Tranexamic acid (TXA)				
Elwatidy et al, 2008	Double-blinded RCT	64 (32)	-273	No data
Wong et al, 2008	Double-blinded RCT	147 (74)	-397*	1.01
Farrokhi et al, 2011	Double-blinded RCT	76 (38)	-67	No data
Tsutomimoto et al, 2011	Nonblinded RCT	40 (20)	-14.3	No data
Yagi et al, 2012	Retrospective cohort study	106 (63)	-466	No complications
Wang et al, 2013	Nonblinded RCT	60 (30)	-28.4	No data
Raksakietisak et al, 2015	Double-blinded RCT	78 (39)	-250	No data
Colomina et al, 2017	Double-blinded RCT	95 (51)	-332*	2.45
Shi et al, 2017	Double-blinded RCT	96 (46)	-85*	0.30
ϵ-Aminocaproic acid (EACA)				
Urban et al, 2001	Nonblinded RCT	35 (18)	No data	0.31
Florintino-Pineda et al, 2004	Double-blinded RCT	36 (17)	-99	No complications
Berenholtz et al, 2009	Double-blinded RCT	91 (50)	-335	0.37
TXA and EACA				
Peters et al, 2015	Double-blinded RCT	32 (13)	No data	2.19
Lu et al, 2018	Meta-analysis of 12 RCTs	937 (465)	-127	0.62

Abbreviations: EBL, intraoperative estimated blood loss; RCT, randomized controlled trial.

* $P < .05$.

Table 4. Topical Hemostatic Summary (Source⁹⁵).

Agent Class	Trade Names	Mechanism of Action	Level of Evidence ^a
Passive agents			
Bone wax	Generic	Mechanical intercalation within trabecular bone	I
Gelatin-based sponge	Gelfoam, Gelfilm, Surgifoam	Mechanical swelling and compression. When soaked in thrombin, activation of coagulation pathway	I
Oxidized, regenerated cellulose	Surgicel	Mechanical swelling and compression. When soaked in thrombin, activation of coagulation pathway	I
Microfibrillar collagen	Avitene, Ultrafoam	Forms scaffold for platelet aggregation and clot formation	I
Active agents			
Antifibrinolytics	—	Inhibition of plasminogen activation, Antifibrinolytic agent stabilizes fibrin clots	A: Supporting
ϵ -Aminocaproic acid	Amicar		
Tranexamic acid	Lysteda		
Fibrin sealant	Evicel, Tisseel	Two components (human fibrinogen and thrombin). Thrombin cleaves the fibrinogen to create a fibrin plug.	I
Flowable hemostatic matrix	Floseal, Surgiflo	Two components (bovine or porcine gelatin matrix and thrombin powder in calcium chloride solution) mixed in a syringe, resulting in mechanical tamponade and fibrin clot formation	A: Supporting
Recombinant activated factor VII (eptacog α)	NovoSeven, AryoSeven	Promotes thrombin generation, resulting in formation of a stable fibrin plug.	A: Supporting

^aGrade A: Good evidence (level I studies with consistent findings) for or against recommending intervention. Grade B: Fair evidence (Level II-III studies with consistent findings) for or against recommending intervention. Grade C: Conflicting or poor-quality evidence (level IV-V studies) not allowing a recommendation. Grade I: There is insufficient evidence to make a recommendation.

Topical Hemostatic Agents

Although the use of topical hemostatic is ubiquitous, the evidence establishing their ability to minimize blood loss or need for allogeneic blood transfusion is sparse with only mild evidence supporting their efficacy at reducing blood loss. This may be due to the tendency to employ them in larger procedures with higher anticipated blood loss. These agents mechanistically reduce blood loss through a combination of mechanical

occlusion of bleeding vessels (bone wax, gelatin sponge), platelet coagulation (microfibrillar collagen), and/or activation of the common clotting pathway (flowable matrix). Of note, expandable cellulose hemostatic agents should be used with caution in the absence of posterior spinal elements as they may cause neural compression.⁹³ All have been deemed relatively safe, and in the authors' experience, they are all effective at safely reducing blood loss.⁹⁴ A summary of the most commonly employed agents and their efficacy is presented in Table 4.

Intraoperative Cell Salvage

A final intervention capable of minimizing the effect of blood loss during spine surgery is the use of intraoperative cell salvage (ICS). ICS works by draining fluid and blood from the dissection cavity and filtering out clotting factors, platelets, and other debris to form an RBC-enriched unit that can then be returned to the patient. The use of this technology has been most thoroughly reported in the field of pediatric deformity, where ICS has been demonstrated to reduce the need for allogeneic blood transfusion.^{96,97} One recent study on the use of ICS in scoliosis surgery showed a significant decrease in the rate of allogeneic blood transfusion—6% versus 55% in those not treated with ICS.⁹⁸

One caveat of ICS is that it requires a minimum blood loss in order to produce a transfusable unit; the size of the blood loss is dictated by the size of the transfusion bowl. Because of this minimum transfusion requirement, the cost-effectiveness of ICS depends on the expected transfusion volume. In patients with high expected blood loss, such as those undergoing surgery for adolescent idiopathic scoliosis, ICS has been found to be cost-neutral compared to allogeneic blood transfusion.⁹⁹ Most studies have found ICS to have a very low complication profile, though at least one study has reported acute kidney injury in the setting of ICS transfusion.¹⁰⁰

Viscoelastic Testing: Rotational Thromboelastometry and Thromboelastography

The ability to monitor the coagulation properties of a patient's blood in real time can potentially make a substantial difference in the overall blood loss and risk of allogeneic transfusion. Failure to recognize increasing bleeding diathesis can lead to run-away hemorrhage. Conventional means of assessing a patient's coagulation status focus on the use of periodic blood draws, which are then tested to determine the activated partial thromboplastin time (aPTT)—a measure of the intrinsic and common coagulation pathways—and the international normalized ratio (INR)—a means of testing the extrinsic and common pathways. Unfortunately, these tests are often slow to result and possibly inaccurate, especially in the operating room.¹⁰¹ Viscoelastic methods are an alternative to these that is gaining attention in spine literature.¹⁰²⁻¹⁰⁴

Viscoelastic methods describe 2 classes of point-of-care tests that emulate sluggish venous blood flow in a small sample of patient blood obtained intraoperatively.¹⁰⁵ The size, stiffness, and time to clot are measured and interpreted to provide an estimate of the adequacy of the patient's clotting ability. Two variations of this technology—rotational thromboelastometry (ROTEM) and thromboelastography (TEG)—exist. The technologies differ slightly in their set-up and required reagents but have been demonstrated to be similarly accurate in direct comparisons.¹⁰⁶ Two recent reviews found both technologies were associated with decreased rates of transfusion of red cells, plasma, and platelets compared with other means of assessing a patient's transfusion needs intraoperatively.^{107,108}

Additionally, Guan et al¹⁰² and Naik et al¹⁰⁴ have published their experiences using ROTEM for patients undergoing elective spine surgery. Naik and colleagues¹⁰⁴ reported that the use of ROTEM significantly decreased intraoperative plasma transfusion requirements and was associated with a cost savings of nearly \$2000 per patient. By comparison, Guan et al¹⁰² observed a significant decrease in total intraoperative red cell, plasma, and total blood product transfusion volumes. Additionally, the impact of ROTEM remained significant on multivariate analysis, independent of surgical invasiveness, preoperative INR and hematocrit, and TXA use. These results have been replicated in other surgical fields, including pediatric neurosurgery,¹⁰⁹ cardiac surgery,¹¹⁰ and liver transplantation.¹¹¹

The biggest drawback of viscoelastic testing methods is that they require additional machinery and training of the anesthesia personnel. To our knowledge, the ability of the small interval costs savings to offset these hardware and personnel training costs has not been evaluated. As a result, we believe insufficient evidence exists to recommend the use of these interventions at small volume centers. However, we do recommend that surgeons at high volume centers with viscoelastometry-trained anesthesia staff, consider using ROTEM or TEG to help reduce transfusion requirements and total care costs.

Postoperative Drain Use

Postoperative, “hidden” blood loss may also substantially contribute to postoperative anemia and the need for transfusion, with prior studies suggesting that these losses may account for 40% to 47% of total blood loss.^{112,113} The use of closed suction drains postoperatively is one intervention that has been suggested to decrease these hidden losses. The theoretical benefits of drains derive from the avoidance of neural element compression and excessive subfascial fluid pressure. Unfortunately, the same negative pressure changes that mediate these effects may also increase incisional drainage and surgical site hematoma formation. For this reason, the current state of spine literature does not allow for a general recommendation.^{114,115} However, we generally place drains for patients undergoing open posterior procedures involving more than 2 levels owing to their ability to decrease rates of wound infection and return to the operating room for wound revision.¹¹⁶

Conclusion

Major spine surgery can be associated with significant intraoperative blood loss. Factoring in the expected operation duration, surgical approach/exposure employed, and surgical complexity is extremely important in planning hemodynamics perioperatively; every effort should be made to minimize blood loss and to avoid transfusion (we weakly recommend a threshold of 7-8 g/dL unless symptomatic). Aside from patient counseling, preoperative optimization includes discontinuation of anticoagulation prior to surgery; the exact timeframe for discontinuation is dictated by the elimination half-life of the drug. Additionally, many surgeons advise discontinuation of aspirin

and other NSAIDs at least 1 week prior to surgery, though the evidence substantiating this recommendation is mixed. Finally, in healthy patients slated for procedures with high anticipated blood loss and for whom allogeneic transfusion is likely, preoperative autologous blood donation may help to reduce the rates of transfusion. However, when this is pursued, it should be done early enough to allow resolution of the post-plebotomy anemia, which could be facilitated by erythropoietin and iron supplementation.

Intraoperative maneuvers available to minimize blood loss include positioning to reduce intraabdominal pressure and maintenance of normothermia. The use of TXA, bipolar sealer electrocautery, and topical hemostatic agents (eg, oxidized regenerated cellulose, microfibrillar collagen, gelatin sponges, flowable agents) should be strongly considered in cases with larger exposures and higher anticipated blood loss. Hypotensive anesthesia (MAP <65 mm Hg) can also facilitate lower blood loss, though we caution against its routine use due to potential catastrophic ischemic neural injury. In our opinion, the MAP should be maintained above 80 mm Hg while manipulating neural elements to avoid neuromonitoring abnormalities. Finally, cell salvage should be considered in patients with high estimated blood loss, especially where allogeneic transfusion is not an option (eg, due to patient beliefs or rare patient blood type).










Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Many of the authors have affiliations with organizations with financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in some of the products mentioned in the study. There are no conflicts of interest in reference to any product mentioned in the content of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This supplement was supported by funding from AO Spine North America.

ORCID iD

Zach Pennington  <https://orcid.org/0000-0001-8012-860X>
 Paul M. Arnold  <https://orcid.org/0000-0002-4622-7695>
 John G. DeVine  <https://orcid.org/0000-0002-8958-2996>
 Michael G. Fehlings  <https://orcid.org/0000-0002-5722-6364>
 George M. Ghobrial  <https://orcid.org/0000-0003-1032-8491>
 Fan Jiang  <https://orcid.org/0000-0002-7673-0267>
 Jefferson R. Wilson  <https://orcid.org/0000-0001-5965-0305>
 Daniel M. Sciubba  <https://orcid.org/0000-0001-7604-434X>
 Samuel K. Cho  <https://orcid.org/0000-0001-7511-2486>

References

- Rajae SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: analysis of trends from 1998 to 2008. *Spine (Phila Pa 1976)*. 2012;37:67-76.
- Ristagno G, Beluffi S, Tanzi D, et al. Red blood cell transfusion need for elective primary posterior lumbar fusion in a high-volume center for spine surgery. *J Clin Med*. 2018;7:E19.
- Willner D, Spennati V, Stohl S, Tosti G, Aloisio S, Bilotta F. Spine surgery and blood loss: systematic review of clinical evidence. *Anesth Analg*. 2016;123:1307-1315.
- Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery for degenerative conditions. *Spine (Phila Pa 1976)*. 2005;30:1441-1447.
- Bible JE, Mirza M, Knaub MA. Blood-loss management in spine surgery. *J Am Acad Orthop Surg*. 2018;26:35-44.
- Hu SS. Blood loss in adult spinal surgery. *Eur Spine J*. 2004;13(suppl 1):S3-S5.
- Pauyo T, Verma N, Marwan Y, Aoude A, Khashan M, Weber MH. Canadian Consensus for the prevention of blood loss in spine surgery. *Spine (Phila Pa 1976)*. 2017;42:E50-E55.
- Basques BA, Anandasivam NS, Webb ML, et al. Risk factors for blood transfusion with primary posterior lumbar fusion. *Spine (Phila Pa 1976)*. 2015;40:1792-1797.
- Berenholtz SM, Pronovost PJ, Mullany D, et al. Predictors of transfusion for spinal surgery in Maryland, 1997 to 2000. *Transfusion*. 2002;42:183-189.
- Butler JS, Burke JP, Dolan RT, et al. Risk analysis of blood transfusion requirements in emergency and elective spinal surgery. *Eur Spine J*. 2011;20:753-758.
- Janssen SJ, Braun Y, Wood KB, Cha TD, Schwab JH. Allogeneic blood transfusions and postoperative infections after lumbar spine surgery. *Spine J*. 2015;15:901-909.
- Kato S, Chikuda H, Ohya J, et al. Risk of infectious complications associated with blood transfusion in elective spinal surgery—a propensity score matched analysis. *Spine J*. 2016;16:55-60.
- Schwarzkopf R, Chung C, Park JJ, Walsh M, Spivak JM, Steiger D. Effects of perioperative blood product use on surgical site infection following thoracic and lumbar spinal surgery. *Spine (Phila Pa 1976)*. 2010;35:340-346.
- Blanchette CM, Wang PF, Joshi AV, Asmussen M, Saunders W, Kruse P. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. *Eur Spine J*. 2007;16:353-363.
- Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. *Transfusion*. 2010;50:753-765.
- Purvis TE, Goodwin CR, De la Garza-Ramos R, et al. Effect of liberal blood transfusion on clinical outcomes and cost in spine surgery patients. *Spine J*. 2017;17:1255-1263.
- Reeves BC, Murphy GJ. Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery. *Curr Opin Cardiol*. 2008;23:607-612.
- Aoude A, Nooh A, Fortin M, et al. Incidence, predictors, and postoperative complications of blood transfusion in thoracic and lumbar fusion surgery: an analysis of 13 695 patients from the American College of Surgeons National Surgical Quality Improvement Program Database. *Global Spine J*. 2016;6:756-764.
- Morcos MW, Jiang F, McIntosh G, et al. Predictors of blood transfusion in posterior lumbar spinal fusion: a Canadian Spine

- Outcome and Research Network Study. *Spine (Phila Pa 1976)*. 2018;43:E35-E39.
20. Zhang L, Liao Q, Zhang T, Dai M, Zhao Y. Blood transfusion is an independent risk factor for postoperative serious infectious complications after pancreaticoduodenectomy. *World J Surg*. 2016;40:2507-2512.
 21. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*. 2008;300:2867-2878.
 22. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. *J Clin Pharmacol*. 2000;40:1109-1120.
 23. Baschera D, Oberle J, Grubhofer F, Schmid SL. Perioperative use of anticoagulant and platelet-inhibiting medications for elective spine surgery: results of a nationwide survey. *J Neurol Surg A Cent Eur Neurosurg*. 2018;79:398-407.
 24. Zhang C, Wang G, Liu X, Li Y, Sun J. Safety of continuing aspirin therapy during spinal surgery: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2017;96:e8603.
 25. Cuellar JM, Petrizzo A, Vaswani R, Goldstein JA, Bendo JA. Does aspirin administration increase perioperative morbidity in patients with cardiac stents undergoing spinal surgery? *Spine (Phila Pa 1976)*. 2015;40:629-635.
 26. Goes R, Muskens IS, Smith TR, Mekary RA, Broekman MLD, Moojen WA. Risk of aspirin continuation in spinal surgery: a systematic review and meta-analysis. *Spine J*. 2017;17:1939-1946.
 27. Park JH, Ahn Y, Choi BS, et al. Antithrombotic effects of aspirin on 1- or 2-level lumbar spinal fusion surgery: a comparison between 2 groups discontinuing aspirin use before and after 7 days prior to surgery. *Spine (Phila Pa 1976)*. 2013;38:1561-1565.
 28. Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on switching platelet P2Y₁₂ receptor-inhibiting therapies. *Circulation*. 2017;136:1955-1975.
 29. Columbo JA, Lambour AJ, Sundling RA, et al. A meta-analysis of the impact of aspirin, clopidogrel, and dual antiplatelet therapy on bleeding complications in noncardiac surgery. *Ann Surg*. 2018; 267:1-10.
 30. Chu EW, Chernoguz A, Divino CM. The evaluation of clopidogrel use in perioperative general surgery patients: a prospective randomized controlled trial. *Am J Surg*. 2016;211:1019-1025.
 31. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. *Clin Cardiol*. 2015;38:555-561.
 32. Asperg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS₂, and CHA₂DS₂-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. *Eur Heart J*. 2016;37: 3203-3210.
 33. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. *Chest*. 2010;137: 263-272.
 34. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. *J Am Coll Cardiol*. 2011;58:395-401.
 35. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. *J Am Heart Assoc*. 2013;2:e000250.
 36. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. *JAMA Intern Med*. 2016;176:473-482.
 37. Wang CZ, Moss J, Yuan CS. Commonly used dietary supplements on coagulation function during surgery. *Medicines (Basel)*. 2015;2:157-185.
 38. Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. *Hong Kong Med J*. 2002;8:123-130.
 39. Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. *Anaesthesia*. 2002;57:889-899.
 40. Goodnough LT, Marcus RE. Effect of autologous blood donation in patients undergoing elective spine surgery. *Spine (Phila Pa 1976)*. 1992;17:172-175.
 41. Solves P, Carpio N, Moscardo F, et al. Results of a preoperative autologous blood donation program for patients undergoing elective major spine surgery. *Transfus Apher Sci*. 2013;49:345-348.
 42. Kelly MP, Zebala LP, Kim HJ, et al; International Spine Study Group. Effectiveness of preoperative autologous blood donation for protection against allogeneic blood exposure in adult spinal deformity surgeries: a propensity-matched cohort analysis. *J Neurosurg Spine*. 2016;24:124-130.
 43. Joseph SA Jr, Berekashvili K, Mariller MM, et al. Blood conservation techniques in spinal deformity surgery: a retrospective review of patients refusing blood transfusion. *Spine (Phila Pa 1976)*. 2008;33:2310-2315.
 44. Vargas-Pabon M, Diaz-Trapiella A, Hurtado MJ, Diaz Varela N, Cerra Sabio JL. Erythropoietin as adjuvant to pre-operative autologous blood donation in total hip arthroplasty: new algorithm for use. *Transfus Apher Sci*. 2005;33:91-97.
 45. Cha CW, Deible C, Muzzonigro T, Lopez-Plaza I, Vogt M, Kang JD. Allogeneic transfusion requirements after autologous donations in posterior lumbar surgeries. *Spine (Phila Pa 1976)*. 2002; 27:99-104.
 46. PROCRI[®] (Epoetin alfa) for injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s51991b1.pdf. Accessed July 20, 2019.
 47. Frank SM, Abazyan B, Ono M, et al. Decreased erythrocyte deformability after transfusion and the effects of erythrocyte storage duration. *Anesth Analg*. 2013;116:975-981.
 48. Park CK. The effect of patient positioning on intraabdominal pressure and blood loss in spinal surgery. *Anesth Analg*. 2000; 91:552-557.
 49. Akinci IO, Tunali U, Kzy AA, et al. Effects of prone and jack-knife positioning on lumbar disc herniation surgery. *J Neurosurg Anesthesiol*. 2011;23:318-322.

50. Böstman O, Hyrkäs J, Hirvensalo E, Kallio E. Blood loss, operating time, and positioning of the patient in lumbar disc surgery. *Spine (Phila Pa 1976)*. 1990;15:360-363.
51. Schur MD, Blumstein GW, Seehausen DA, Ross PA, Andras LM, Skaggs DL. Intraoperative hypothermia is common, but not associated with blood loss or transfusion in pediatric posterior spinal fusion. *J Pediatr Orthop*. 2018;38:450-454.
52. Tedesco NS, Korpi FP, Pazdernik VK, Cochran JM. Relationship between hypothermia and blood loss in adult patients undergoing open lumbar spine surgery. *J Am Osteopath Assoc*. 2014;114:828-838.
53. Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. *Anesthesiology*. 2008;108:71-77.
54. Billeter AT, Hohmann SF, Druen D, Cannon R, Polk HC Jr. Unintentional perioperative hypothermia is associated with severe complications and high mortality in elective operations. *Surgery*. 2014;156:1245-1252.
55. Sun Z, Honar H, Sessler DI, et al. Intraoperative core temperature patterns, transfusion requirement, and hospital duration in patients warmed with forced air. *Anesthesiology*. 2015;122:276-285.
56. Lee HY, Kim G, Shin Y. Effects of perioperative warm socks-wearing in maintaining core body temperature of patients undergoing spinal surgery. *J Clin Nurs*. 2018;27:1399-1407.
57. Hasankhani H, Mohammadi E, Moazzami F, Mokhtari M, Naghizadh MM. The effects of intravenous fluids temperature on perioperative hemodynamic situation, post-operative shivering, and recovery in orthopaedic surgery. *Can Oper Room Nurs J*. 2007;25:20-27.
58. Verma K, Lonner B, Dean L, Vecchione D, Lafage V. Reduction of mean arterial pressure at incision reduces operative blood loss in adolescent idiopathic scoliosis. *Spine Deform*. 2013;1:115-122.
59. Kamel I, Zhao H, Koch SA, Brister N, Barnette RE. The use of somatosensory evoked potentials to determine the relationship between intraoperative arterial blood pressure and intraoperative upper extremity position-related neurapraxia in the prone surrender position during spine surgery: a retrospective analysis. *Anesth Analg*. 2016;122:1423-1433.
60. Silverstein JW, Matthews E, Mermelstein LE, DeWal H. Causal factors for position-related SSEP changes in spinal surgery. *Eur Spine J*. 2016;25:3208-3213.
61. Grundy BL, Nash CL Jr, Brown RH. Deliberate hypotension for spinal fusion: prospective randomized study with evoked potential monitoring. *Can Anaesth Soc J*. 1982;29:452-462.
62. Dutton RP. Controlled hypotension for spinal surgery. *Eur Spine J*. 2004;13(suppl 1):S66-S71.
63. Street JT, Andrew Glennie R, Dea N, et al. A comparison of the Wiltse versus midline approaches in degenerative conditions of the lumbar spine. *J Neurosurg Spine*. 2016;25:332-338.
64. Barsoum WK, Klika AK, Murray TG, Higuera C, Lee HH, Krebs VE. Prospective randomized evaluation of the need for blood transfusion during primary total hip arthroplasty with use of a bipolar sealer. *J Bone Joint Surg Am*. 2011;93:513-518.
65. Frank SM, Wasey JO, Dwyer IM, Gokaslan ZL, Ness PM, Kebash KM. Radiofrequency bipolar hemostatic sealer reduces blood loss, transfusion requirements, and cost for patients undergoing multilevel spinal fusion surgery: a case control study. *J Orthop Surg Res*. 2014;9:50.
66. Fukui D, Kawakami M, Nakao SI, et al. Reduced blood loss and operation time in lumbar posterolateral fusion using a bipolar sealer. *Eur Spine J*. 2017;26:726-732.
67. Hardesty CK, Gordon ZL, Poe-Kochert C, Son-Hing JP, Thompson GH. Bipolar sealer devices used in posterior spinal fusion for neuromuscular scoliosis reduce blood loss and transfusion requirements. *J Pediatr Orthop*. 2018;38:e78-e82.
68. Mankin KP, Moore CA, Miller LE, Block JE. Hemostasis with a bipolar sealer during surgical correction of adolescent idiopathic scoliosis. *J Spinal Disord Tech*. 2012;25:259-263.
69. Lan T, Hu SY, Yang XJ, et al. The efficacy of bipolar sealer on blood loss in spine surgery: a meta-analysis. *Eur Spine J*. 2017;26:1796-1802.
70. Lu D, Ding WG, Sheng HF, Xu XW, Ying XZ, Xu WX. The efficacy and safety of using a bipolar sealer to prevent blood loss in spine surgery: a meta-analysis. *Int J Surg*. 2017;46:37-46.
71. Wang X, Sun G, Sun R, et al. Bipolar sealer device reduces blood loss and transfusion requirements in posterior spinal fusion for degenerative lumbar scoliosis: a randomized control trial. *Clin Spine Surg*. 2016;29:E107-E111.
72. Farrow LS, Smith TO, Ashcroft GP, Myint PK. A systematic review of tranexamic acid in hip fracture surgery. *Br J Clin Pharmacol*. 2016;82:1458-1470.
73. Shi H, Ou Y, Jiang D, Quan Z, Zhao Z, Zhu Y. Tranexamic acid reduces perioperative blood loss of posterior lumbar surgery for stenosis or spondylolisthesis: a randomized trial. *Medicine (Baltimore)*. 2017;96:e5718.
74. Lu VM, Ho YT, Nambiar M, Mobbs RJ, Phan K. The perioperative efficacy and safety of antifibrinolytics in adult spinal fusion surgery: a systematic review and meta-analysis. *Spine (Phila Pa 1976)*. 2018;43:E949-E958.
75. Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. *Spine (Phila Pa 1976)*. 2009;34:2096-2103.
76. Peters A, Verma K, Slobodyanyuk K, et al. Antifibrinolytics reduce blood loss in adult spinal deformity surgery: a prospective, randomized controlled trial. *Spine (Phila Pa 1976)*. 2015;40:E443-E449.
77. Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. *Spine (Phila Pa 1976)*. 2001;26:1152-1156.
78. Florentino-Pineda I, Thompson GH, Poe-Kochert C, Huang RP, Haber LL, Blakemore LC. The effect of Amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study. *Spine (Phila Pa 1976)*. 2004;29:233-238.
79. DiNardo J. *Pediatric Cardiac Anesthesia*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
80. Tsutsumimoto T, Shimogata M, Ohta H, Yui M, Yoda I, Misawa H. Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. *Spine (Phila Pa 1976)*. 2011;36:1913-1918.

81. Cheriyan T, Maier SP 2nd, Bianco K, et al. Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis. *Spine J*. 2015;15:752-761.
82. da Rocha VM, de Barros AG, Naves CD, et al. Use of tranexamic acid for controlling bleeding in thoracolumbar scoliosis surgery with posterior instrumentation. *Rev Bras Ortop*. 2015;50:226-231.
83. Li G, Sun TW, Luo G, Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. *Eur Spine J*. 2017;26:140-154.
84. Elwatidy S, Jamjoom Z, Elgamel E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. *Spine (Phila Pa 1976)*. 2008;33:2577-2580.
85. Wong J, El Beheiry H, Rampersaud YR, et al. Tranexamic acid reduces perioperative blood loss in adult patients having spinal fusion surgery. *Anesth Analg*. 2008;107:1479-1486.
86. Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up. *Mol Genet Metab Rep*. 2017;13:69-75.
87. Verma K, Kohan E, Ames CP, et al. A comparison of two different dosing protocols for tranexamic acid in posterior spinal fusion for spinal deformity: a prospective, randomized trial. *Int J Spine Surg*. 2015;9:65.
88. Lum ZC, Manoukian MAC, Pacheco CS, Nedopil AJ, Giordani M, Meehan JP. Intravenous tranexamic acid versus topical aminocaproic acid: which method has the least blood loss and transfusion rates? *J Am Acad Orthop Surg Glob Res Rev*. 2018;2:e072.
89. Xie J, Hu Q, Huang Q, Ma J, Lei Y, Pei F. Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis. *Thromb Res*. 2017;153:28-36.
90. Zhang P, Liang Y, Chen P, Fang Y, He J, Wang J. Intravenous versus topical tranexamic acid in primary total hip replacement: a meta-analysis. *Medicine (Baltimore)*. 2016;95:e5573.
91. Desai BD, Taylor DG, Chen CJ, et al. Utility of topical tranexamic acid for adult patients with spinal deformity and contraindications to systemic tranexamic acid: initial experience and report of 2 cases [published online January 25, 2019]. *J Neurosurg Spine*. doi:10.3171/2018.9.SPINE18204
92. Sun Y, Jiang C, Li Q. A systematic review and meta-analysis comparing combined intravenous and topical tranexamic acid with intravenous administration alone in THA. *PLoS One*. 2017;12:e0186174.
93. Cho SK, Yi JS, Park MS, et al. Hemostatic techniques reduce hospital stay following multilevel posterior cervical spine surgery. *J Bone Joint Surg Am*. 2012;94:1952-1958.
94. Ma L, Dai L, Yang Y, Liu H. Comparison the efficacy of hemorrhage control of Surgiflo Haemostatic Matrix and absorbable gelatin sponge in posterior lumbar surgery: a randomized controlled study. *Medicine (Baltimore)*. 2018;97:e13511.
95. Baird EO, McAnany SJ, Lu Y, Overley SC, Qureshi SA. Hemostatic agents in spine surgery: a critical analysis review. *JBJS Rev*. 2015;3:01874474-201501000-00001.
96. Huët C, Salmi LR, Fergusson D, Koopman-van Gemert AW, Rubens F, Laupacis A. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators. *Anesth Analg*. 1999;89:861-869.
97. Liang J, Shen J, Chua S, et al. Does intraoperative cell salvage system effectively decrease the need for allogeneic transfusions in scoliotic patients undergoing posterior spinal fusion? *A prospective randomized study*. *Eur Spine J*. 2015;24:270-275.
98. Bowen RE, Gardner S, Scaduto AA, Eagan M, Beckstead J. Efficacy of intraoperative cell salvage systems in pediatric idiopathic scoliosis patients undergoing posterior spinal fusion with segmental spinal instrumentation. *Spine (Phila Pa 1976)*. 2010;35:246-251.
99. Alamanda VK, Massengill DL, Rozario N, et al. Blood loss trends and financial implications in adolescent idiopathic scoliosis. *Clin Spine Surg*. 2018;31:E418-E421.
100. Minkara AA, Lin AY, Vitale MG, Roye DP Jr. Acute kidney injury secondary to cell saver in posterior spinal fusion. *Spine Deform*. 2017;5:430-434.
101. Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. *Hematol J*. 2003;4:373-378.
102. Guan J, Cole CD, Schmidt MH, Dailey AT. Utility of intraoperative rotational thromboelastometry in thoracolumbar deformity surgery. *J Neurosurg Spine*. 2017;27:528-533.
103. Naik BI, Durieux ME, Knisely A, et al. SEER sonorheometry versus rotational thromboelastometry in large volume blood loss spine surgery. *Anesth Analg*. 2016;123:1380-1389.
104. Naik BI, Pajewski TN, Bogdonoff DI, et al. Rotational thromboelastometry-guided blood product management in major spine surgery. *J Neurosurg Spine*. 2015;23:239-249.
105. Shen L, Tabaie S, Ivascu N. Viscoelastic testing inside and beyond the operating room. *J Thorac Dis*. 2017;9(suppl 4):S299-S308.
106. Kinard TN, Christie A, Greilich PE, Sarode R. Comparison of thromboelastography (TEG) with rotational thromboelastometry (ROTEM) in surgical patients. *Blood*. 2013;122:3659.
107. Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. *Anaesthesia*. 2017;72:519-531.
108. Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products—a systematic review and meta-analysis. *Scand J Trauma Resusc Emerg Med*. 2017;25:39.
109. Haas T, Goobie S, Spielmann N, Weiss M, Schmutz M. Improvements in patient blood management for pediatric craniostomy surgery using a ROTEM[®]-assisted strategy—feasibility and costs. *Paediatr Anaesth*. 2014;24:774-780.
110. Vasques F, Spiezia L, Manfrini A, et al. Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study. *J Anesth*. 2017;31:286-290.
111. Smart L, Mumtaz K, Scharpf D, et al. Rotational thromboelastometry or conventional coagulation tests in liver transplantation: comparing blood loss, transfusions, and cost. *Ann Hepatol*. 2017;16:916-923.

112. Xu D, Ren Z, Chen X, et al. The further exploration of hidden blood loss in posterior lumbar fusion surgery. *Orthop Traumatol Surg Res.* 2017;103:527-530.
113. Smorgick Y, Baker KC, Bachison CC, Herkowitz HN, Montgomery DM, Fischgrund JS. Hidden blood loss during posterior spine fusion surgery. *Spine J.* 2013;13:877-881.
114. Liu JM, Chen WZ, Fu BQ, Chen JW, Liu ZL, Huang SH. The use of closed suction drainage in lumbar spinal surgery: is it really necessary? *World Neurosurg.* 2016;90:109-115.
115. Waly F, Alzahrani MM, Abduljabbar FH, et al. The outcome of using closed suction wound drains in patients undergoing lumbar spine surgery: a systematic review. *Global Spine J.* 2015;5: 479-485.
116. Herrick DB, Tanenbaum JE, Mankarious M, et al. The relationship between surgical site drains and reoperation for wound-related complications following posterior cervical spine surgery: a multicenter retrospective study. *J Neurosurg Spine.* 2018;29: 628-634.